NCT05700617 Cardiac Power Output in Cardiogenic Shock Patients
| NCT ID | NCT05700617 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Chicago |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2023-07-06 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 5 participants in total. It began in 2023-07-06 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
Eligibility Criteria
Inclusion Criteria: 1. LVEF ≤ 40% 2. Referred for RHC for: 1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR 2. Accurate assessment of invasive hemodynamics due to worsening clinical status, OR 3. Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR 4. Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI 3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2 4. Age ≥ 18 years-old 5. Intent for admission based on RHC data Exclusion Criteria: 1. eGFR \< 30 ml/min/1.73 m2 2. Severe, non-revascularized coronary artery disease 3. Concurrent acute coronary syndrome 4. Age \< 18 years-old 5. History of significant ventricular arrhythmia without an ICD
Contact & Investigator
Valluvan Jeevanandam, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT05700617 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05700617 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05700617 currently recruiting?
Yes, NCT05700617 is actively recruiting participants. Contact the research team at donsager1@uchgicagomedicine.org for enrollment information.
Where is the NCT05700617 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT05700617 clinical trial?
NCT05700617 is sponsored by University of Chicago. The principal investigator is Valluvan Jeevanandam, MD at University of Chicago. The trial plans to enroll 5 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.